Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
NPR has obtained the government's $5.3 billion contract for the first 10 million courses of Paxlovid, an antiviral pill for COVID-19. Here's what's in it. -
The Biden administration wants to buy and send a billion free at-home COVID tests to Americans. Here's what we know so far about the contracts in terms of price, timeline and more.
-
Paxlovid and molnupiravir have been authorized for emergency use to keep COVID-19 patients out of the hospital, but don't expect to be able to go to your usual pharmacy and get them. -
Omicron has many more mutations than previous variants of concern, a fact that raises questions about how effective existing vaccines will be against the new form of the coronavirus. -
Former scientific head of Operation Warp Speed Moncef Slaoui explains why he is confident in existing vaccines' protection against omicron and how soon a variant-specific booster could be developed.
-
There's a new, heavily mutated COVID-19 variant called omicron. Scientists tell us what's known so far about it, what's not yet known, and what this all means for public health.
-
How much money have Pfizer and Moderna made off their COVID-19 vaccines? They're shaping up to be the most lucrative pharmaceutical products ever.
-
Pfizer says it is willing to share rights to its COVID-19 pill, Paxlovid. It's an oral antiviral drug that can be taken outside the hospital, which could be a help to low income countries.
-
Kids who need hormone-blocking drugs to prevent premature puberty — or delay it if they're trans — have lost a more affordable option. The remaining nearly identical drug costs eight times more. -
Kids who need a hormone-blocking drug to prevent premature puberty have lost an off-label option. The company that makes the medicine, which is 1/8 the cost of the FDA-approved version, withdrew it.
